The company conducted a survey of business and operational leaders across the life science sector on the trends and technologies that may revolutionise the industry during the coming years.
The research suggested an increasing appetite for Industry 4.0 – which focuses on using data and information to revolutionise GMP manufacturing.
Nearly 60% of those surveyed believe that Industry 4.0 will drive the most change in life science during the next 5 years, with 75% of those aiming to invest in people to take advantage of emerging technologies.
It also uncovered the main motivators for technology investment were cost and time saving, with more than 70% of respondents citing these reasons.
Following on from these findings, Zenith published a whitepaper, Industry 4.0: Revolutionising Life Science Manufacturing through Connected Systems and Data,’written by Global Services Director, David Staunton and MES Project Manager, Ryan McInerney.
The paper examines technological advances that are driving the next phase of pharmaceutical manufacturing, improving quality and reducing waste.
David Staunton said: “The life science industry has used data and information to drive improvements in GMP Manufacturing for decades and there is now an opportunity to take it to the next level.”
“The foundation of life science GMP manufacturing is to know your process and industry 4.0 allows us to stay true to who we are, while at the same time revolutionising GMP manufacturing.”
